BTIG Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $4

Futu NewsJan 11 23:32 · Ratings

Buy Rating for Nektar Therapeutics: Promising Clinical Trial Strategy and Efficacy of Rezpeg

TipRanksJan 11 23:27 · Ratings

Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $7

Futu NewsJan 10 20:34 · Ratings

Express News | Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis

BreakingsJan 10 20:00

Nektar Therapeutics (NKTR) Gets a Buy From Piper Sandler

TipRanksJan 10 19:46 · Ratings

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

BenzingaJan 8 20:41